



**Oregon Prescription Drug Affordability Board Regular Meeting
Wednesday, March 18, 2026
Minutes approved by the board on April 15, 2026**

Web link to the meeting video: <https://youtu.be/ggp9LW277PM>

Web link to the meeting materials: <https://dfr.oregon.gov/pdab/Documents/20260318-PDAB-document-package.pdf>

Call to order: Chair Shelley Bailey called the meeting to order at 8:03 a.m.

Roll call:

Present: Chair Shelley Bailey, Vice Chair Dan Hartung, Lauri Hoagland, Dan Kennedy, Michele Koder, Chris Laman, John Murray

Absent: None

Board declarations of conflict of interest and meetings with entities or individuals related to board activities: John Murray, Lauri Hoagland, Shelley Bailey provided statements. View at video minute [00:01:02](#).

Approval of board minutes: Chair Bailey approved by consensus the Feb. 18, 2026, minutes as shown on [Pages 2-3](#) of the agenda materials. View at video minute [00:03:07](#).

PDAB program update: Sarah Young, PDAB executive director, provided a program update. View the video at minute [00:03:34](#).

General public comment: Public comment was received from the following individuals who signed up in advance: Dharia McGrew, PhRMA; Primo Castro, BIO; Katie Chandra, Genentech; Lorren Sandt, Caring Ambassadors; Andrew Kiehlbauch, OSPIRG; and Marris Alden, Regence BlueCross BlueShield of Oregon. The board received 12 written comments, which are posted on the [PDAB website](#). View at video minute [00:14:53](#).

Vote on final 2025 drug review report with recommendations: The Board discussed and voted on policy concepts 1) Patient out-of-pocket cap and 2) Point-of-sale rebate pass-through, as presented on [Pages 8-10](#) of the agenda materials. The board voted to approve both policy concepts for inclusion in the 2025 Drug Review Report to the Oregon Legislature. The final [report](#) was posted on the PDAB website after the board meeting. The discussion and vote begin at video minute [00:34:38](#).



MOTION to approve the 2025 drug review report with Policy 1 patient out-of-pocket cap model as discussed by the board today.

Board Vote:

Motion: John Murray

Second: Lauri Hoagland

Yes: Lauri Hoagland, Chris Laman, John Murray, Vice Chair Dan Hartung, Chair Shelley Bailey

No: Dan Kennedy, Michele Koder

Absent: None

MOTION PASSED 5-2

MOTION to approve the 2025 drug review report with Policy 2 point-of-sale rebate pass through model as discussed by the board today.

Board Vote:

Motion: John Murray

Second: Lauri Hoagland

Yes: Lauri Hoagland, Michele Koder, John Murray, Chair Shelley Bailey

No: Dan Kennedy, Chris Laman, Vice Chair Dan Hartung

Absent: None

MOTION PASSED 4-3

Vote clarification: Dan Kennedy stated for the record that he is in favor of Policy 1 and Policy 2, although he voted no on both. His understanding was the board would have a third vote combining both policies, which he supports.

MOTION to approve the 2025 drug review report with Policy 1 and Policy 2 to send to the Oregon Legislature as discussed by the board today.

Board Vote:

Motion: John Murray

Second: Dan Kennedy

Yes: Lauri Hoagland, Dan Kennedy, Michele Koder, Chris Laman, John Murray, Vice Chair Dan Hartung, Chair Shelley Bailey

No: None

Absent: None

MOTION PASSED 7-0

Legislative update: Jesse O'Brien, policy manager for the Division of Financial Regulation, provided a recap of the 2026 Oregon Legislative session as shown on [Pages 4-7](#) of the agenda materials. View at video minute [01:30:30](#).



2026 drug review: Select a subset of drugs to prioritize for review under OAR 925-200-0010:

The board discussed and voted on a subset list of prescription drugs and insulin products for prioritization for the 2026 reviews under OAR-925-200-0010. See [Pages 22-27](#) of the agenda materials for the roadmap, process document, board memo, and web links to the data dashboard and spreadsheets. The drug review information is also posted on the [data page](#) of the PDAB website. The approved subset list of drugs is included in Appendix A and [posted on the PDAB website](#). The discussion and vote begin at video timestamp [01:45:17](#).

MOTION to approve Ocrevus, Tremfya, Skyrizi, Xolair, Keytruda, Verzenio, Xeljanz, Jardiance, Mounjaro, and Ozempic for the board's subset list for 2026 affordability reviews.

Board Vote:

Motion: Chris Laman

Second: Dan Kennedy

Yes: Lauri Hoagland, Dan Kennedy, Michele Koder, Chris Laman, John Murray, Vice Chair Dan Hartung, Chair Shelley Bailey

No: None

Absent: None

MOTION PASSED 7-0

MOTION to include Humulin 500, the Kwikpen and the concentrated solution, to the subset list for affordability review.

Board Vote:

Motion: Dan Hartung

Second: Dan Kennedy

Yes: Lauri Hoagland, Dan Kennedy, Michele Koder, Chris Laman, John Murray, Vice Chair Dan Hartung, Chair Shelley Bailey

No: None

Absent: None

MOTION PASSED 7-0

Announcements: Chair Bailey announced the next board meeting will be April 15, 2026. View at video minute [03:46:38](#).

Adjournment: Chair Bailey adjourned the meeting at 12 p.m. with all board members in agreement. View at video minute [03:46:46](#).